Vasomune Therapeutics is a private biotechnology company developing therapies to target diseases associated with blood vessel (vascular) dysfunction and destabilization. The inner most layer of blood vessels is made up of individual endothelial cells that regulate the passage of immune and inflammatory cells to a site of injury. In many different disease states, dysfunctional vasculature results in an exaggerated inflammatory response. Vascular dysfunction can lead to, or exacerbate many different diseases such as cardiovascular, renal, pulmonary and oncology. The company’s lead compound is Vasculotide, a Tie2 receptor agonist that has demonstrated positive therapeutic effect in many different diseases associated with vascular dysfunction. Vasomune Therapeutics, spun out of MaRS Innovation, Sunnybrook Hospital and Health Sciences Centre at the University of Toronto in 2012, is translating a strong foundation of academic science into clinical practice. Vasomune’s initial programs focus on targeting acute and chronic diseases of the kidney. The lead development program takes aim at treating Acute Kidney Injury (AKI), a significant unmet medical need. While several distinct clinical paths exist for the development of Vasculotide, the decision to pursue AKI is based on a strong, third-party validated preclinical data set and converging evidence that vascular dysfunction lies at the core of AKI.
Something looks off?